Skip to content
Bomb Report – Lifestyle
Author:
Octapharma
/C O R R E C T I O N — Octapharma/
September 11, 2026
Fewer Blood Components Transfused with fibryga® Than Cryoprecipitate, Secondary Analysis of Prespecified FIBRES Subgroups Reports
September 9, 2026
Octapharma to build $1.5 billion state-of-the-art critical care manufacturing facility in Rock Hill, SC
July 29, 2026
Octapharma USA Announces Expanded FDA Approval of wilate® for von Willebrand Disease Prophylaxis in Children Younger Than 6 Years
July 8, 2026